Atara Biotherapeutics ATRA Declines 697 Support Test Looms as Biotech Sentiment Softens Prediction Market Investments Continue Despite Regulatory Uncertainty Corporate Earnings Calls Reveal Ongoing Commitment SBUX Q1 2026 Earnings EPS Beats Estimates by 142 Revenue Unreported Stock Dips 13 DeepSeek AI Draws Silicon Valley Praise Despite Chip Constraints